News / Cannabis Control Commission Opens Investigation into Marijuana Products Containing Corydalis Yanhusuo, Issues Precautionary Bulletin
For Immediate Release
August 12, 2022
Director of Communications
Cannabis Control Commission Opens Investigation into Marijuana Products Containing Corydalis Yanhusuo, Issues Precautionary Bulletin
WORCESTER—The Cannabis Control Commission (Commission) issued a bulletin Friday to inform Massachusetts licensees, Certifying Healthcare Providers, Patients, Caregivers, and consumers about potential adverse health effects that have been reported related to the consumption of Marijuana-infused Products (MIPs) containing Corydalis rhizome extract (Corydalis), otherwise known as Corydalis yanhusuo.
Corydalis has been associated with an elevated risk of liver injury, a.k.a., hepotoxicity, and may pose a risk to Massachusetts residents’ public health, safety, and welfare. As a result, the Commission is currently investigating this ingredient, including one if its alkaloids, tetrahydropalmatine (THP).
On July 22, the Colorado Department of Revenue’s Marijuana Enforcement Division and the Colorado Department of Public Health and Environment released an informational notification citing reports claiming that an MIP called 1906 Midnight Drops, produced by Sima Sciences, LLC in their state, have led to certain health issues including potential liver injury.
1906 Midnight Drops also appear to be available for sale in the Commonwealth and are manufactured using Corydalis. The Commission recently received a similar report from a Massachusetts medical provider concerning this product. At this time, the Commission is not issuing a product recall or limiting the sale of specific products or product categories in Massachusetts.
“The health and safety of patients and consumers is of utmost importance to the Commission, which is why we immediately opened an investigation into products that contain Corydalis and are issuing this precautionary bulletin to enable the public to make informed decisions about what they put in their bodies,” said Commission Executive Director Shawn Collins. “As the Commission’s regulations require all MIPs to include a product label listing their ingredients, patients and consumers may wish to check any purchases for Corydalis and consult with a healthcare provider they trust for additional guidance. The agency will continue to inform the public of important developments as we learn more about this ingredient.”
Any patient or consumer who experiences adverse health effects from consuming 1906 Midnight Drops, or any other marijuana product containing Corydalis, should seek immediate medical attention. Such events may be reported to the Commission by calling (774) 415-0200 or emailing Inspections@CCCMass.com.
For more information, visit the Enforcement Announcements page at MassCannabisControl.com, contact the Commission by phone (774-415-0200) or email (Commission@CCCMass.com), or follow the agency on Facebook and Twitter.
Subscribe for updates from the Cannabis Control Commission.